Overview
- 3 public-safe observations are available for this inspection.
- 3 structured CFR citations are represented.
- 2 investigators are tied to this Form 483.
Inspectional observations
Each observation cites the regulation FDA found the firm out of compliance with.
29 May 2026
ISO 13485:2016 Clause 5.6.1
QMS not reviewed by top management at documented planned intervals
Cited by Alexandria L Capuano, Richard E Evoy
29 May 2026
ISO 13485:2016 Clause 7.4.1
Supplier monitoring and re-evaluation not planned
Cited by Alexandria L Capuano, Richard E Evoy
29 May 2026
ISO 13485:2016 Clause 8.2.4
Internal audits not conducted to ensure QMS meets requirements and is effective
Cited by Alexandria L Capuano, Richard E Evoy
Inspected site
MCMolecularMD CorpPortland, United States
Inspection team
RERichard E Evoy
Cited regulations
CFR citations associated with this Form 483.
| Citation | What it covers | Cited |
|---|---|---|
| ISO 13485:2016 Clause 5.6.1 | Cited across public-safe Form 483 observations | 1x |
| ISO 13485:2016 Clause 7.4.1 | Cited across public-safe Form 483 observations | 1x |
| ISO 13485:2016 Clause 8.2.4 | Cited across public-safe Form 483 observations | 1x |
Full 483 report
Get the verbatim text of all 3 observations
The full inspection record, as Atlas holds it, so your team sees exactly what was cited and how it was answered.
- The site's full inspection history around this Form 483
- Whether these citations escalated to a warning letter
- The investigators involved and the citations they repeat elsewhere